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Background: A significant subset of patients with atrial fibrillation and high risk of stroke, are unable or have significant contraindications to 
treatment with oral anticoagulants. Device occlusion of the left atrial appendage (LAA) has been shown to be equivalent to antigoagulation in eligble 
patients. We report our initial acute results and technique for the LAA occlusion with the Amplatzer Cardiac Plug (ACP), a device comprising of a 
retaining lobe for deployment within the LAA and an occluding disc for covering the LAA ostium.
Methods: The ACP was deployed in patients with relative or absolute contraindications to oral anticoagulation. TEE was performed prior to the 
procedure for device sizing and thrombus exclusion. All procedures were performed under general anesthetic with fluoroscopic and TEE control. 
Device sizing was based upon a 2-5mm upsizing of a zone 1cm from the LAA ostium by TEE and angiography. Criteria for device release were 
compression of the retaining lobe, separation of the retaining lobe from the occlusive disc and concavity of the occlusive disc. Confirmation of 
residual flow was performed with echo and fluoroscopy.
Results: 34 patients underwent LAA occlusion. Mean CHADS2 score was 3.5 with 29/34 having scores > 2. 18 had suffered previous strokes. Most 
frequent contraindications to anticoagulants were GI bleeding 11, other bleeding 8, poor compliance 5 and falls 5. All devices were successfully 
placed. In a single case, due to an extremely large LAA 1/3 deployment criteria was not met. Median device size was 24mm (16-30). In 8 cases 
(24%) a second device was taken due to incorrect sizing, only 2 of these in the last 25 cases. There were no neurological complcations. In a single 
case LAA perforation was noted during deployment and acutely drained with no long term sequelae. In a patient with severe mitral incompetence 
and poor left ventricular function, post procedure pulmonary edema occurred, delaying discharge for one day.
Conclusions: In a high risk group of patients the ACP was used to safely and successfully acutely occlude the LAA based upon set criteria ensuring 
device stability. Device sizing improved with experience.
